We have recently shown that treatment of HNSCC patients with pembrolizumab, a monoclonal blocking antibody against PD1 (αPD-1), increases KCa3.1 and Kv1.3 activities in CD8+ TILs and PBTs, along with their Ca2+ fluxing and migratory abilities (Newton et al., 2020). The gene discussed is CD8A; the disease is head and neck squamous cell carcinoma.